Published in Cancer Weekly, March 23rd, 1998
The completion of this Phase I/II trial marks the achievement of an other significant milestone by Imutec Pharma. The results of this trial aids in discussions with potential partners regarding the licensing of marketing and distribution rights for Virulizin, which is in line with the company's business strategy of out-licensing products prior to Phase III clinical trials.
"I am pleased to report that enrollment of our current trial is now...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.